| Dermatitis |
1 |
1 |
| Child |
0 |
0.98 |
| Otolaryngology |
0 |
0.71 |
| Acne |
0 |
0.41 |
| Toxicology |
0 |
0.3 |
| Atopic Dermatitis |
0 |
0.99 |
| California |
0 |
0.27 |
| Pruritus |
0 |
0.27 |
| Quality of Life |
0 |
0.27 |
| Pediatric Dermatology |
0 |
0.26 |
| Biologic Therapy |
0 |
0.23 |
| Patient Safety |
0 |
0.23 |
| Topical Corticosteroid |
0 |
0.19 |
| Adolescent Medicine |
0 |
0.18 |
| Adverse Effects |
0 |
0.18 |
| Allergy |
0 |
0.18 |
| Alopecia Areata |
0 |
0.18 |
| Anxiety |
0 |
0.18 |
| Corticosteroids |
0 |
0.18 |
| Food and Drug Administration (FDA) |
0 |
0.18 |
| Hospital |
0 |
0.18 |
| Asthma |
0 |
0.17 |
| Food Allergy |
0 |
0.17 |
| Alopecia |
0 |
0.16 |
| Anxiety Disorder |
0 |
0.16 |
| Depression |
0 |
0.16 |
| Learning Disability |
0 |
0.13 |
| Psoriasis |
0 |
0.13 |
| Substance Abuse |
0 |
0.13 |
| Thromboembolism |
0 |
0.13 |
| Upper Respiratory Tract Infection |
0 |
0.13 |
| Addiction |
0 |
0.11 |
| Abuse |
0 |
0.09 |
| Arkansas |
0 |
0.09 |
| Bone |
0 |
0.09 |
| Disability |
0 |
0.09 |
| Interleukin |
0 |
0.09 |
| Nausea |
0 |
0.09 |
| Plaque Psoriasis |
0 |
0.09 |
| Pollutant |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Respiratory Tract |
0 |
0.09 |
| Rhinitis |
0 |
0.09 |
| Tolerance |
0 |
0.09 |
| Urticaria |
0 |
0.09 |
| Venous Thromboembolism (VTE) |
0 |
0.09 |
| ADHD |
0 |
0.08 |
| Headache |
0 |
0.08 |
| Herpes Zoster |
0 |
0.08 |
| Neutropenia |
0 |
0.08 |
| Skin and Soft Tissue Infection |
0 |
0.08 |
| Urticaria and Angioedema |
0 |
0.08 |